Alencar Herlen, Funovics Martin A, Figueiredo Jose, Sawaya Heloisa, Weissleder Ralph, Mahmood Umar
Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Bldg 149, 13th St, Room 5408, Charlestown, MA 02129, USA.
Radiology. 2007 Jul;244(1):232-8. doi: 10.1148/radiol.2441052114. Epub 2007 May 16.
To prospectively evaluate the ability of micro-fiberoptic catheters, which simultaneously record white light and near-infrared (NIR) images, to reveal colonic neoplasms after the intravenous administration of activatable "smart" probes that increase in NIR fluorescence subsequent to protease activation.
The institutional animal care committee approved all animal experiments. CT26 tumor cells were orthotopically implanted into the descending colon of C57BL6/J mice (n=10). Thirteen days later, mice intravenously received either 2 nmol of a protease-sensing probe that had cathepsin B as a major activator (n=5) or saline (control animals [n=5]). One day later, animals were noninvasively examined to the point of the splenic flexure by using microcatheter imaging. Excised colons were subsequently evaluated with epifluorescence imaging, histologic examination, and cathepsin B immunohistochemistry. Student t test was used for statistical analysis, with P<.05 considered to indicate a significant difference.
Results with fiberoptic imaging demonstrated that all tumors were visible with the protease-activatable probe, even when they were not readily apparent at white light imaging. A target-to-background ratio (TBR) of 8.86 for tumor to adjacent normal mucosa was achieved in the NIR channel after probe administration (P=.001), whereas white light images resulted in a TBR of 1.14 (P>.5) based on luminosity. The tumoral NIR fluorescence intensity was more than 30-fold greater in probe-injected animals than in control animals, indicating that essentially all of the signal recorded in lesions was from activatable probe administration. Results of immunohistochemistry confirmed cathepsin B overexpression in the tumor compared with adjacent mucosa.
The use of NIR imaging microcatheters combined with protease-activatable smart probes results in a beacon effect that highlights tumors with high TBRs; this technique thus may be a potentially useful adjunct to white light colonoscopy in the future.
前瞻性评估微光纤导管在静脉注射可激活的“智能”探针后显示结肠肿瘤的能力,该探针在蛋白酶激活后近红外(NIR)荧光增强,可同时记录白光和近红外(NIR)图像。
机构动物护理委员会批准了所有动物实验。将CT26肿瘤细胞原位植入C57BL6/J小鼠的降结肠(n = 10)。13天后,小鼠静脉注射2 nmol以组织蛋白酶B为主要激活剂的蛋白酶传感探针(n = 5)或生理盐水(对照动物[n = 5])。一天后,使用微导管成像对动物进行无创检查至脾曲。随后对切除的结肠进行落射荧光成像、组织学检查和组织蛋白酶B免疫组织化学评估。采用Student t检验进行统计分析,P<0.05被认为具有显著差异。
光纤成像结果表明,即使在白光成像中不易察觉,所有肿瘤在蛋白酶可激活探针下均可见。给药后,近红外通道中肿瘤与相邻正常黏膜的靶背景比(TBR)达到8.86(P = 0.001),而基于亮度的白光图像TBR为1.14(P>0.5)。注射探针的动物肿瘤近红外荧光强度比对照动物高30倍以上,表明病变中记录的信号基本上都来自可激活探针的给药。免疫组织化学结果证实肿瘤中组织蛋白酶B的表达高于相邻黏膜。
近红外成像微导管与蛋白酶可激活智能探针的结合产生了信标效应,突出了高TBR的肿瘤;因此,该技术未来可能成为白光结肠镜检查的潜在有用辅助手段。